Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.
June 29th 2022
Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.
Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.
July 6th 2022
Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.
Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.
July 14th 2022
Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.
An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.
July 21st 2022
Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.
Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease
July 28th 2022
Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.
Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.
August 4th 2022
After reviewing other novel bispecific antibodies including talquetamab, cevostamab, and elranatamab in RRMM, panelists consider how these agents compare and might be selected for specific patients.
Shared insight on the adverse event profiles of novel bispecific antibody therapies, with specific focus on how CRS can be adequately managed by the health care team.
August 11th 2022
Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.
Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.
August 18th 2022
Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.
August 25th 2022
Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.
Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.